A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4
Copyright © 2018 The Authors. Production and hosting by Elsevier B.V. All rights reserved..
Dipeptidyl peptidase-4 (DPP-4) inhibitors not only improve impaired glucose tolerance in diabetes, but also have pleiotropic extra-pancreatic effects such as preconditioning effect for myocardial ischemia-reperfusion injury. Here, we investigated the anti-remodeling effects of linagliptin, a DPP-4 inhibitor, by use of DPP-4-deficient rats. After the induction of myocardial infarction (MI), Fischer 344 rats with inactivating mutation of DPP-4 were orally administrated with a DPP-4 inhibitor, linagliptin (5 mg kg-1·day-1), or vehicle in drinking water for 4 weeks. Linagliptin did not affect hemodynamic status, body weight, and infarct size. In echocardiography, linagliptin tended to improve left ventricular (LV) systolic function, and significantly improved LV diastolic function, surprisingly. Interstitial fibrosis in marginal region and macrophage infiltration were significantly lower in the linagliptin group than those in the vehicle group. Fibrosis-related gene expressions, such as collagen I and transforming growth factor-β1 (TGF-β1), and inflammation-related expressions, such as macrophage chemotactic protein 1 and matrix metalloproteinase-2 (MMP-2), were significantly suppressed in marginal area of the linagliptin-treated rats compared with the vehicle rats. The TGF-β1 and MMP-2 protein levels were attenuated by linagliptin in DPP-4-deficient cardiac fibroblasts. Linagliptin can attenuate MI-induced cardiac remodeling via a DPP-4-independent pathway.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:139 |
|---|---|
| Enthalten in: |
Journal of pharmacological sciences - 139(2019), 2 vom: 15. Feb., Seite 112-119 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yamaguchi, Takehiro [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 17.04.2019 Date Revised 17.04.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jphs.2018.12.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM292671288 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM292671288 | ||
| 003 | DE-627 | ||
| 005 | 20231225073627.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jphs.2018.12.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0975.xml |
| 035 | |a (DE-627)NLM292671288 | ||
| 035 | |a (NLM)30638989 | ||
| 035 | |a (PII)S1347-8613(18)30226-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yamaguchi, Takehiro |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4 |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.04.2019 | ||
| 500 | |a Date Revised 17.04.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2018 The Authors. Production and hosting by Elsevier B.V. All rights reserved. | ||
| 520 | |a Dipeptidyl peptidase-4 (DPP-4) inhibitors not only improve impaired glucose tolerance in diabetes, but also have pleiotropic extra-pancreatic effects such as preconditioning effect for myocardial ischemia-reperfusion injury. Here, we investigated the anti-remodeling effects of linagliptin, a DPP-4 inhibitor, by use of DPP-4-deficient rats. After the induction of myocardial infarction (MI), Fischer 344 rats with inactivating mutation of DPP-4 were orally administrated with a DPP-4 inhibitor, linagliptin (5 mg kg-1·day-1), or vehicle in drinking water for 4 weeks. Linagliptin did not affect hemodynamic status, body weight, and infarct size. In echocardiography, linagliptin tended to improve left ventricular (LV) systolic function, and significantly improved LV diastolic function, surprisingly. Interstitial fibrosis in marginal region and macrophage infiltration were significantly lower in the linagliptin group than those in the vehicle group. Fibrosis-related gene expressions, such as collagen I and transforming growth factor-β1 (TGF-β1), and inflammation-related expressions, such as macrophage chemotactic protein 1 and matrix metalloproteinase-2 (MMP-2), were significantly suppressed in marginal area of the linagliptin-treated rats compared with the vehicle rats. The TGF-β1 and MMP-2 protein levels were attenuated by linagliptin in DPP-4-deficient cardiac fibroblasts. Linagliptin can attenuate MI-induced cardiac remodeling via a DPP-4-independent pathway | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Dipeptidyl peptidase-4 | |
| 650 | 4 | |a Fibrosis | |
| 650 | 4 | |a Left ventricular diastolic function | |
| 650 | 4 | |a Macrophage | |
| 650 | 4 | |a Myocardial infarction | |
| 650 | 7 | |a Dipeptidyl-Peptidase IV Inhibitors |2 NLM | |
| 650 | 7 | |a Tgfb1 protein, rat |2 NLM | |
| 650 | 7 | |a Transforming Growth Factor beta1 |2 NLM | |
| 650 | 7 | |a Linagliptin |2 NLM | |
| 650 | 7 | |a 3X29ZEJ4R2 |2 NLM | |
| 650 | 7 | |a DPP4 protein, rat |2 NLM | |
| 650 | 7 | |a EC 3.4.14.5 |2 NLM | |
| 650 | 7 | |a Dipeptidyl Peptidase 4 |2 NLM | |
| 650 | 7 | |a EC 3.4.14.5 |2 NLM | |
| 650 | 7 | |a Matrix Metalloproteinase 2 |2 NLM | |
| 650 | 7 | |a EC 3.4.24.24 |2 NLM | |
| 650 | 7 | |a Mmp2 protein, rat |2 NLM | |
| 650 | 7 | |a EC 3.4.24.24 |2 NLM | |
| 700 | 1 | |a Watanabe, Ayano |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Masako |e verfasserin |4 aut | |
| 700 | 1 | |a Shiota, Masayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Osada-Oka, Mayuko |e verfasserin |4 aut | |
| 700 | 1 | |a Sano, Soichi |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshiyama, Minoru |e verfasserin |4 aut | |
| 700 | 1 | |a Miura, Katsuyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Kitajima, Shojiro |e verfasserin |4 aut | |
| 700 | 1 | |a Matsunaga, Shinji |e verfasserin |4 aut | |
| 700 | 1 | |a Tomita, Shuhei |e verfasserin |4 aut | |
| 700 | 1 | |a Iwao, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Izumi, Yasukatsu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of pharmacological sciences |d 2003 |g 139(2019), 2 vom: 15. Feb., Seite 112-119 |w (DE-627)NLM124584721 |x 1347-8648 |7 nnns |
| 773 | 1 | 8 | |g volume:139 |g year:2019 |g number:2 |g day:15 |g month:02 |g pages:112-119 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jphs.2018.12.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 139 |j 2019 |e 2 |b 15 |c 02 |h 112-119 | ||